Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P3, N=1099, Completed, Imperial College London | Active, not recruiting --> Completed

P3, N=536, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Aug 2025

P4, N=352, Active, not recruiting, Boston Medical Center | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Apr 2026

No significant differences were observed in anal dysplasia regression or anal microbiota composition over 12 months. Given the lack of short-term secondary benefit and persistence of HPV incidence, MSM with HIV require continued routine anal cancer screening.

P3, N=700, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Nov 2025 --> May 2026

P=N/A, N=2500, Not yet recruiting, Indiana University | Trial primary completion date: Feb 2028 --> Aug 2028

P1/2, N=50, Not yet recruiting, Ohio State University

P4, N=750, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Apr 2026 --> Dec 2026 | Recruiting --> Active, not recruiting

P4, N=150000, Active, not recruiting, Karolinska Institutet

P2, N=525, Not yet recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2026 --> Apr 2028 | Initiation date: Dec 2025 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Apr 2028

P4, N=400, Recruiting, Zhejiang Provincial Center for Disease Control and Prevention

We found no consistent difference in geometric mean nAb titers between mice strains that received 9vHPV at any time point tested or in median HPV16- or HPV18-specific plasma cell frequencies. Thus, we conclude the magnitude and durability of nAb responses to 9vHPV vaccination do not depend on DNA sensing pathways.